GlassScriptPhysician profile
Denise R Moore
NPI 1790098580
$1,108.88
in general payments reported to CMS, 2019-2025
25 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $156 · 2023: $164 · 2024: $294 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.07 |
| Education | $105.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $287.26 | 2022-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $105.72 | 2025 | |
| Novartis Pharmaceuticals Corporation | $78.63 | 2024 | |
| Abbvie INC. | $76.89 | 2021-2025 | |
| Gilead Sciences, INC. | $71.11 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $60.48 | 2021-2025 | Opdivo |
| Glaxosmithkline, LLC. | $45.97 | 2023-2024 | Trelegy Ellipta |
| Emd Serono, INC. | $42.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $40.03 | 2023-2024 | Imfinzi |
| Jazz Pharmaceuticals INC. | $34.30 | 2025 | |
| Pfizer INC. | $33.53 | 2023-2024 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Daiichi Sankyo INC. | $24.50 | 2025 | Enhertu |
| Taiho Oncology, INC. | $20.85 | 2021 | |
| Janssen Biotech, INC. | $20.05 | 2024 | Talvey, Tecvayli, Darzalex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $16.11 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.93 | 2025 | Monoferric |
| Novo Nordisk INC | $15.50 | 2021 | |
| Dova Pharmaceuticals | $15.00 | 2021 | |
| Amgen INC. | $14.54 | 2023 | Xgeva, Vectibix, Nplate |
| Springworks Therapeutics, INC. | $14.31 | 2024 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $13.96 | 2024 | Libtayo |
| Kite Pharma, INC. | $12.96 | 2022 | |
| Merck Sharp & Dohme LLC | $11.60 | 2021 | |
| Blueprint Medicines Corporation | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.